Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
Read more on PharmaceuticalOnline
Categories: Metastatic Breast Cancer Tags: combination, enrollment, initiate, Merrimack, MM121, Pharmaceuticals, Phase, SanofiAventis, Study
Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease
Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease
Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom …
Read more on News-Medical-Net
Categories: Breast Cancer Risks Tags: Chagas, chronic, Clinical, Disease, initiate, Merck, Phase, posaconazole, proofofconcept, proposes, Study